J. JORDÁN, I. IKUTA, J. GARCÍA-GARCÍA, S. CALLEJA and T. SEGURA. Stroke pathophysiology: Management challenges and new treatment advances (minireview). J. Physiol. Biochem., 63 (3), 261-278, 2007. Stroke is the second leading cause of death and the first cause of lost disabilityadjusted years in developed countries. During the past decade, new developments in thrombolytic therapy have led to the implementation of emergency intervention protocols for the treatment of ischemic stroke, replacing the widespread sense of therapeutic nihilism in the past. Treatment with rtPA has shown to be effective within the first 3 hours following stroke onset and the FDA and the European Medical Agency (EMEA) have approved its use. Acknowledging the urgency and intricacies of stroke, Stroke Units allow the monitoring of physiological parameters in the acute phase of stroke and are considered an important management tool that can significantly improve the quality of care provided to the patient. The concept of neuroprotective therapy for acute ischemic stroke to salvage tissue at risk and improve functional outcome is based on sound scientific principles and extensive preclinical animal studies demonstrating efficacy. However, most neuroprotective drugs in clinical trials have failed, possibly due to inadequate preclinical testing or flawed clinical development programs. Several new treatment strategies are under development and are being tested. This review is directed at understanding the management of acute ischemic stroke pathophysiology. We address the management challenges and new treatment advances by integrating the knowledge of possible pharmacological targets for acute ischemic stroke. We hope to shed new light upon the controversy surrounding the management of acute ischemic stroke in an attempt to elucidate why failed clinical trials continue to occur despite promising neuroprotective preclinical studies.
Stroke is the main cause of lost disability-adjusted life years and ranks second after ischemic heart disease as a cause of death in developed countries. The incidence of stroke increases exponentially with age but varies among countries. Approximately 15 million people suffer a stroke every year, and in spite of the medical advances, 5 million patients will die and at least 5 million will be left disabled. Of the 3 million Americans who have survived a stroke, 2 million will sustain some permanent disability, with an overall cost to the nation of $40 billion per year. Stroke is not a simple disease. It can be ischemic or hemorrhagic. The former is quite more common. Embolic blockage of a blood vessel is the most frequent cause of ischemic stroke, wich can involve small or large arteries, intracranial or extracranially and other mechanisms as local thrombosis or hypoperfusion can occur. Stroke evolution is quite variable and can be influenced by various factors such as age, sex racial background hypotension, fever, or hyperglycemia. It can be influenced by comorbidities and concurrent medications, responsible for about 80% of the approximately 700,000 strokes in the United States each year. Probably due to this enormous variability, despite many years of intensive research, treatment of ischemic stroke continues to be one of the major challenges in current medicine. In this review we are going to present the accepted drugs as well as some of the latest trials that try to add new therapeutic alternatives. Herein, we have divided the text in the two main pharmacologic approaches: restoration of cerebral perfusion and neuroprotection.
Pharmacology of restoration of cerebral perfusion
Ischemic stroke is a dynamic process where a series of excitotoxic, inflammatory and microvascular mechanisms take place that lead to tissue necrosis. However, some ischemic brain tissue may be salvageable if reperfusion occurs before damage becomes irreversible. Initially after arterial occlusion, a poorly perfused central core area is surrounded by an area of dysfunction caused by metabolic and ionic disturbances but with preserved structural integrity (the ischemic penumbra). The ischemic penumbra ( Fig. 1 ) has been documented in the laboratory animal as still viable brain tissue surrounding the irreversibly damaged ischemic core. Thus, current efforts of all acute stroke therapy are aimed at that portion of ischemic region which is potentially salvageable. Saving as much of the penumbra as possible is the main target of acute stroke therapy, and is the theoretical basis behind the reperfusion concept. The goal of reperfusion treatment is to restore cerebral blood flow, and the main clinical tools to achieve this objective are thrombolytic drugs. These agents enhance the endogenous formation of plasmin from plasminogen, what in turn can potentially dissolve the blood clot occluding a cerebral vessel by disrupting fibrin. rt-PA is the only thrombolytic agent currently licensed to treat selected patients with acute ischemic stroke in the first three hours after stroke onset. In 1996, rt-PA was granted FDA approval largely on the basis of the National Institute of Neurological Disorders and Stroke (NINDS) rt-PA study (77) . In this pivotal study, 624 patients were randomly assigned treatment with rt-PA or placebo. The outcome at 3 months was significantly better in the treated group. The study only included patients presenting within 3 hours of symptom onset and approximately one half was treated within 90 minutes. In the European Union, however, regulatory authorities did not approve the use of rt-PA until 2002, and at the moment it is still limited to a restricted license at specialist centers. The situation in Europe is probably due to the unsuccessful result of the two European Cooperative Acute Stroke Studies (ECASS and ECASS 2) (37, 32) . In these two large trials, IV rt-PA was not more effective than placebo in improving neurological outcomes 3 months after stroke. It appears quite likely that time was a limiting factor in the ECASS studies since these trials treated patients up to 6 hours after stroke. However, a post-hoc analysis concluded that patients treated within 3 hours appeared to benefit from rt-PA treatment. In fact, community studies have confirmed the safety and usefulness of the drug in routine clinical practice when administered within the first 3 hours after stroke symptom onset (2, 30, 74) . Recently finished is the multinational Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST) which was designed to evaluate the safety and efficacy of IV rt-PA under routine clinical use when administered within 3 hours of symptom onset in acute ischemic stroke patients. This large, international, multi-center, open study, has confirmed the safety and efficacy of rt-PA within this 3-hour time window (79) . Furthermore, a combined analysis of six randomized control trials (RCTs) of IV rt-PA (31) showed that the sooner patients received thrombolytic therapy, the greater the benefit. This same analysis found that the benefit of IV rt-PA in acute ischemic stroke seems to disappear 4.5 hours after the onset. While the efficacy of thrombolytic agents is very much under the influence of time, other factors will modify the potential expected efficacy. Although it is probable that part of the efficacy of desmoteplase lies in its pharmaceutical properties (higher fibrin specificity and absence of NMDA-mediated neurotoxicity), the DIAS results suggested that thrombolytic therapy may be safe beyond 3 hours if the proper patients were selected. This finding gave hope to stroke investigators that in the near future it will be possible to extend the therapeutic window far beyond 3 hours. However, it has been recently announced that the larger prospective clinical trial DIAS-II does not reproduce the positive effects of the previous study. Other thrombolytic agents, including reteplase, anistreplase, and tenecteplase, in conjunction with new strategies based on evolving multimodal MRI or CT techniques, soon will likely allow for the selection of patients for late IV reperfusion therapy.
Another possibility is ultrasoundenhanced thrombolysis. Ultrasound can induce microstreams within the clot to increase the distribution of rt-PA for improved thrombolysis. Transcranial ultrasound-enhanced intravenous thrombolysis leads to an absolute 20% increase in the rate of middle cerebral artery (MCA) recanalization according to CLOTBUST results (5) . Moreover, transcranial ultrasound has been shown to accelerate clot dissolution in some patients with contraindications for rt-PA, although these preliminary data should be confirmed in the setting of a large trial. Finally, ultrasound in combination with novel microparticles offers further potential for targeted thrombolytic drugs.
Intra-arterial (IA) thrombolysis has been shown effective up to 6 hours after symptom onset in MCA occlusions. IA thrombolysis significantly increases the probability of a favorable outcome 2.3-fold (44) . Although no RCTs have compared IA versus IV thrombolysis, some indirect data suggest a higher rate of recanalization via IA administration. Given that the IA administration takes longer than IV, a combined IV and rescue IA approach has been proposed (23) . This way begins immediately with IV rt-PA and ultrasound monitoring of the MCA artery. If partial or completed recanalization has not been achieved after thirteen minutes, then the patient is moved to angiography and IA thrombolysis is administered. This strategy allows more time to prepare patients for IA thrombolysis without increasing any delay in potential treatment.
Although endovascular interventions of acute ischemic stroke show great promise, available data has been limited. There are some successful reports of angioplasty combined with thrombolysis in patients with occlusions in the vertebrobasilar circulation, but until now both angioplasty and stenting of intracranial vessels remain to be demonstrated as an emergency treatment of stroke. The FDA has recently approved the use of the MERCI device (based in the results of the Mechanical Embolus Removal in Cerebral Embolism trial) for reopening intracranial arteries, although its clinical utility has not yet been established (70) . This option may be particularly important in proximal artery occlusions, nonresponders to thrombolytic agents, and for patients otherwise ineligible for thrombolytic therapy.
Pharmacology of neuroprotection
"Neuroprotection" is a term used to describe the putative effect of interventions protecting the brain from pathological damage. Hundreds of neuroprotective strategies have been shown to improve outcome in animal models of focal cerebral ischemia, but thus far none of them have been shown to be clearly efficacious in patients. However, our increasing knowledge concerning the ischemic cascade is leading to considerable development of pharmacological tools suggesting that each step of this cascade might be a target for cytoprotection. In stroke, the concept of neuroprotection involves inhibition of a cascade of pathological molecular events which occur under ischemia and lead to calcium influx, activation of free radical reactions, and cell death. Following a vessel occlusion, critical decrease in focal cerebral blood flow promote a complex biochemical cascade within ischemic tissue. This ischemia-induced biochemical cascade interferes with glucose metabolism and causes cell Na + pump failure. These events lead to neuronal depolarization and the release of excitotoxic neurotransmitters which are able to cause abrupt necrotic cell death within the infarct core. In the surrounding greater volume of the ischemic tissue (the penumbra area), a dynamic process is initiated (Fig. 1 ). This process also involves intracellular calcium influx, multiple free radical production, and expression of adhesion molecules leading to inflammation and cell death.
It is now clear that a stroke causes different types of cell death. Much like an earthquake, a stroke wreaks havoc around its epicenter, destroying cells in a devastating process called necrosis. But farther away from the epicenter, the stroke's ripple effects cause cells within the penumbra to kill themselves by apoptosis. This slower process can take days, and it ultimately determines the extent of the ensuing spread of brain damage. Programmed cell death is probably the critical process in the evolution of the penumbra area given that it is the main cause of neuronal death in this region. Besides the morphological and biochemical differences between necrosis and apoptosis, the main differential characteristic is that apoptotic pathways allow pharmacological intervention at the three established stages of programmed cell death: activation, commitment and execution. In the first stage, excitotoxic processes include rising calcium ion concentrations and reactive oxygen species formation which promote apoptotic gene expression. Mitochondria, through a process mainly regulated by changes in the permeability of their outer membrane, play a central role in the commitment stage, being considered the point-of-no-return. Finally, in the execution stage, degradation enzyme complexes such as caspases, calpains and endonucleases assume an active role. It is typically considered that only by preventing the first two stages it is possible to avoid neuronal damage, since acting on the execution stage can delay but not prevent impending cell death. So, we are going to review the different strategies that could potentially abort apoptosis in ischemic brain tissue.
The apoptosis activation process involved in stroke includes the alteration of calcium and sodium ion homeostasis due to reversal of the glutamate transporter (Fig. 2) . The subsequent increase of this neurotransmitter at the synapse overactivates the receptors. This increased agonism of receptors results in an increase of cytoplasmic calcium that might depolarize the mitochondria, which will increase the amount of free radicals and lipid peroxidation (Fig. 3) . Stroke excitotoxicity is primarily mediated by several glutamate receptor subtypes, including the NMDA and AMPA receptors (10) . NMDA receptor antagonists were the first neuroprotective agents tested in stroke clinical trials. Despite the lack of unacceptable side effects, no efficacy was found with competitive NMDA antagonists (selfotel) or non-competitive NMDA antagonists (dextrorphan, aptiganel and eliprodil). Activation of the NMDA receptor requires the co-agonist glycine. Studies of the glycine antagonist, gavestinel, found the medication to be safe, but favorable outcomes were not found. Another glycine antagonist, licostinel, was associated with numerous side effects.
The AMPA receptor is the principal mediator of fast excitatory neurotransmission. This ligand-gated cation channel is primarily permeable to sodium rather than calcium. In a variety of animal models, a reduction of infarct volume has been demonstrated with AMPA blockade. First generation AMPA receptor blockers were competitive antagonists, like NBQX, which showed robust neuroprotection in a variety of disease-related animal models. Its clinical use, however, was restricted by very low solubility, inducing kidney precipitation in vivo. Second generation competitive antagonists are available, which do not possess this property. However, none of these second generation competitive antagonists are currently in clinical use. The AMPA antagonist ZK 200775 led to neurological deterioration in a preliminary study. A novel, highly water-soluble, competitive AMPA receptor antagonist, YM872 (Zonampanel), has been identified. Phase I studies showed YM872 was well tolerated at 1.25 mg/kg/h when given as a 24-hour infusion to healthy subjects. Sedation and other CNS-associated adverse events determine the ceiling dose and become more problematic with infusion times exceeding 24 hours. Phase II trial of YM872 in acute ischemic stroke is ongoing. Awaiting the final results of the last studies, a systematic review of trials testing excitatory amino acid antagonists in stroke (51) found no improvements in rates of either death or favorable outcomes with treatment.
Another agent that modulates the glutamate receptor family includes magnesium. Magnesium blocks NMDA receptors, inhibits release of presynaptic excitatory neurotransmitters, and antagonizes voltage-sensitive calcium channels. Due to all of these actions, it was thought that this agent could be useful in the reduction of ischemic brain injury. However, an international phase III trial investigating the efficacy of magnesium in stroke, the IMAGES (Intravenous Magnesium Efficacy in Stroke) trial did not find such benefit (50) . Most patients in this study received magnesium beyond 3 hours. As such, the investigators of the Pilot Study Field Administration of Stroke TherapyMagnesium (FAST-MAG) planned a scaled-up randomized control trial to test magnesium efficacy when the drug was administered in a hyperacute stage (63) . Patients received paramedic-administered magnesium on average within 26 minutes of symptom onset, with safe results. Clinicians noted patient improvement in 20% of the cases, deterioration in 7%, and no change in 73%. A FAST-MAG Phase III Trial is ongoing to evaluate the efficacy of hyperacute, paramedic-initiated magnesium sulfate administration in improving the long-term functional outcome of patients with acute stroke. This adamatane derivate preferentially blocks excessive NDMA receptor activity without disrupting normal activity. Memantine does this through its action as a lowaffinity, noncompetitive open-channel blocker with a relatively rapid off-rate from the channel. The unique and subtle difference of the site of memantine action at the channel pore may explain many advantageous properties of memantine administration. Memantine binds at the "intracellular" magnesium site in the channel pore. In a rat model of stroke, memantine reduces the amount of brain damage by approximately 50% when given as long as 2 hours after the ischemic event (43).
Fig. 3. Ischemia results in rapid loss of high-energy phosphate compounds and generalized depolarization, which induces the reversal of glutamate transporters and the opening of both voltage-dependent and glutamate-regulated calcium channels. These changes lead to a large increase in cytosolic Ca 2+ associated with an alteration of mitochondrial stability. Mitochondrial membrane inestability eventually activates proteases with consequent proteolysis of substrates.
On the other hand, enhancing the activity of the GABA-ergic system may be neuroprotective in acute stroke, as it inhibits presynaptic glutamate release. The neuroprotective effect of diazepam has been demonstrated in global ischemia models in vivo and in vitro (65) . Clomethiazole, a GABA agonist with the property of increasing cellular resistance to glutamate toxicity, was tested in the clinical trial CLASS (Clomethiazole Acute Stroke Study). This trial was unable to show significant efficacy and a subsequent study restricted to patients with total anterior circulation syndrome also failed to show benefit (80) .
Another possibility is blocking the intracellular increase in calcium. Voltagedependent Ca 2+ channels (L-, N-, T-, Pand Q-type) have been widely recognized as an important regulator of the nervous system. Interestingly, several reports have suggested that a blockade or lack of Ntype Ca 2+ channels can suppress the neuronal pathologic processes of ischemic brain injury in animal models. Cilnidipine is a Ca 2+ channel blocker with suppressive effects on L-and N-type Ca 2+ channels that reduced neuronal damage in ischemic rat brains. TAKAHARA et al. proposed that this drug may be suitable for hypertensive patients with a risk of brain attack (72) . As of January 2006, 110 patients had been enrolled in a multi-center, randomized, double-blind, active control, titrated dose, non-inferiority trial, the Cilnidipine Effect on High Blood Pressure and Cerebral Perfusion in Ischemic Stroke Patients with Hypertension (CHERISH). They are going to compare the effect of cilnidipine and losartan (angiotensin II receptor blocker) on cerebral blood flow and blood pressure in hypertensive patients with a previous history of ischemic stroke.
A second approach to block rising intracellular calcium is by buffering intracellular calcium concentration. We can do so by using a calcium chelator such as DP-b99. DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid), which selectively modulates the distribution of metal ions in hydrophobic milieu, and is in clinical development as a neuroprotectant for cerebral ischaemic stroke. Final results in Phase IIB showed a 90-day median change in NIHSS scores of 6.0 and 5.0 points (nonsignificant) in the placebo (n=72) and treatment (n=75) groups, respectively, from the baseline scores of 7-20; and of 5.0 and 8.0 points in the placebo and treatment groups, respectively, (p=0.03) from the baseline scores of 10 -16. Recovery rates for the DP-b99 and placebo groups per modified Rankin scale was 30.6% and 16.0% (p=0.05), per NIHSS was 23.6% and 12.0% (p=0.08), and by either scale was 37.5% and 18.7% (p=0.02), respectively. In Phase IIa, an efficacy evaluation demonstrated significant improvements in clinical stroke outcome assessed with the NIH Stroke Scale (NIHSS) at 2, 7 and 30 days after stroke in patients treated with DP-b99 within 12 hours of the onset of stroke symptoms. There were no significant differences in the number of serious adverse events, cases of death, or causes of death between the DP-b99 and placebo groups (61) .
Sodium channel blockers have also been used in stroke therapy. Lubeluzole is a sodium channel blocker with additional effects on nitric oxide. Although a pilot study suggested that this agent was safe and might reduce the death rate in stroke, subsequent clinical trials found no significant effects in reducing deaths or improving outcomes (15) . Fosphenytoin is a well known anticonvulsant agent that blocks voltage-dependent sodium and calcium channels and prevents glutamate release. However, its clinical efficacy in ischemic stroke has not been demonstrated. Sipatrigine (619C89), a sodium and calcium channel blocker, also failed to have any favorable effect on outcome measures in a phase II clinical trial using a continuous intravenous infusion in acute stroke (49) .
Besides calcium and sodium, reactive oxygen species participate in stroke by activating apoptotic pathways since brain ischemia initiates a complex cascade of metabolic events, several of which involve the generation of nitrogen and oxygen free radicals. In fact, reactive oxygen species activate Bax to induce mitochondrial cytochrome c release and apoptosis in response to chemical ischemia (29) . And reactive oxygen species induce swelling and cytochrome c release but not transmembrane depolarization in isolated rat brain mitochondria (25) . Antioxidant drugs including compounds with free radical scavenging activity (Ebselen, tirilazad), iron chelators (deferoxamine) and antioxidants with free radical trapping properties (NXY-059), and albumin have been examined in experimental models of stroke and evaluated clinically as potential neuroprotective agents. We will now discuss the results of clinical evaluations of these potential stroke modifiers.
Ebselen, a selene-organic compound with antioxidant activity, improves the outcome of acute ischemic stroke. A randomized, double-blind, placebo-controlled trial of ebselen was conducted in patients with complete occlusion of the middle cerebral artery. There was a corresponding significant reduction in the volume of cerebral infarct and an improvement in the outcome of patients who started treatment within 6 hours of onset.
Ebselen might be safe and effective in improving outcomes after stroke, and another clinical trial is under way (82) . On the other hand, preclinical data on tirilazad in animal models of acute ischemic stroke were neither comprehensive nor consistent. So, when studied in man, tirilazad not only did not improve outcome after stroke, but potentially appeared to marginally worsen it (7).
Iron is generally believed to participate in neuronal dysfunction and death through its ability to catalyze (via electron donation) the generation of highly reactive hydroxyl radicals via Fenton reaction chemistry. In this model, hydroxyl radicals modify lipid, protein, and DNA targets to induce cell dysfunction of these cellular constituents. Iron chelators can inhibit Fenton reaction chemistry and prevent neuronal cell injury by sequestering accumulated free iron. However, this pathway of iron chelator-mediated protection remains controversial. The neuroprotective potential of the iron chelator deferoxamine comes from its antioxidant effect as well as its capacity to stabilize the hypoxia-inducible factor-1 (HIF-1) protein expression (discussed later). The safety of deferoxamine in acute stroke patients over 50 years old without known iron overload is currently being tested.
The NXY-059 compound has been purposed to act as a free radical scavenger and was effective in reducing lesion volume and neurological deficits. Recently, the positive results from the first Stroke-Acute-Ischemic-NXY-Treatment (SAINT-I) trial, which followed many of the Stroke Therapy Academic Industry Roundtable (STAIR) guidelines, reinvigorated the enthusiasm for neuroprotection (41) . The STAIR recommendations seek to improve the quality of preclinical research and to ensure that the data gener-ated will enable the selection of those agents most suitable for progression from the laboratory to clinical trials. However, the SAINT-II trial did not reproduce the positive effects on the same primary prespecified outcome measure. In this trial the investigators failed to confirm the efficacy of NXY-059 for the treatment of acute ischemic stroke within 6 hours after the onset of symptoms (69) .
Preclinical studies have suggested that albumin has potentially neuroprotective effects (26, 27) . Recent data from a phase I dose-escalation study provide evidence that human serum albumin is safe after stroke, despite a mild-to-moderate increase in pulmonary edema, even when given with thrombolytic therapy (26) . The study provided preliminary evidence of efficacy, with patients in the highest dose tiers having about an 80% greater chance of good outcome at 3 months than the lower dose tiers (57) . There also seemed to be a synergistic effect between albumin and thrombolytic therapy. A recently published phase I/II clinical trial confirmed the clinical benefit of albumin administered within 24 hours from symptom onset, showing that these effects were dose-and time-related (68) . A more definitive phase-III trial (Albumin-in-Acute Stroke) is underway.
Protein synthesis inhibition occurs in neurons during reperfusion after ischemia, highlighting the likely role that these pathways play in prosurvival versus proapoptotic processes that may be differentially expressed in vulnerable and resistant regions of the reperfused brain tissue. The activation of some transcription factors has been detected in neurons and microglia in the penumbra area. These include the hypoxia-inducible factor-1 (HIF-1), p53, peroxisome proliferatoractivated receptors (PPARs) and S-100β.
The HIF-1 is of the main transcriptional factors regulated by oxygen level. HIF-1 increases the expression of several beneficial genes such as erythropoietin, glucose transporter-1, and vascular endothelial growth factor. As previously commented, the iron chelator deferoxamine stabilizes HIF-1α protein expression. The p53 protein is activated upon detection of stress signals, such as hypoxia and DNA damage. The regulation of p53 functions is tightly controlled through several mechanisms including p53 transcription and translation, protein stability, post-translational modifications, and subcellular localization (28) . So, p53 can be considered a pharmacological target. Blocking p53 expression demonstrably and efficiently protects against cerebral ischemia in experimental models, and this protection includes reduction in rates of apoptosis (36) . Indeed, preclinical studies demonstrate the efficacy of a p53 inhibitor in models of stroke and neurodegenerative disorders, and suggest that drugs that inhibit p53 may reduce the extent of brain damage in related human neurodegenerative conditions. PPARs are endogenous protective factors in cerebral ischemia. Activation of PPAR-γ attenuates the expression of ICAM-1, matrix metalloproteinase MMP-9, and various cytokines in ischemic brain tissue. Activation of PPAR-γ with pioglitazone or other thiazolidinediones might reduce immune reactions, and at the same time release a powerful anti-inflammatory potential in ischemic brains. PPAR agonists decrease the expression of COX-2, an enzyme involved in the production of reactive oxygen species (ROS). PPAR agonists also increase in the expression level of the ROS scavenger Cu-Zn-superoxide dismutase. The PPAR-γ agonist rosiglitazone could be a potential novel therapeutic agent for stroke (46) . Arundic acid (AA; ONO-2506), a novel modulator of astrocyte activation, may improve neuronal survival after stroke by suppressing S-100β‚ protein production in astrocytes. In the presence of ischemia or other biochemical insults, S-100β‚ protein is overexpressed in astrocytes, and in turn induces mRNA expression of iNOS, NGFβ‚ and COX-2. AA reduces cerebral infarct volumes and improves neurological function in rodent surgical models of acute ischemic stroke. AA is active in a wide time window after the onset of neurological injury since astrocyte activation occurs over many hours in both human stroke patients and preclinical stroke models. In seven completed phase I healthy volunteer studies and two previous stroke patient safety studies, AA was well-tolerated. The efficacy of AA in acute stroke treatment should be confirmed in future clinical trials (58) .
Mitochondria are considered the main link between cellular stress signals and the execution of neuronal programmed cell death (34) . Conditions during reperfusion are likely to be conducive to the induction of the permeability transition in mitochondria. Translocation of cytochrome c (Cyt c) from the mitochondria to the cytoplasm is crucial to the commitment step of apoptosis. Calcium-induced Cyt c release, as occurs in neurons during stroke and ischemia, involves rupture of the mitochondrial outer membrane and can be blocked by inhibitors of the mitochondrial permeability transition pore (mPT). Induction of the mPT has been linked to cytotoxicity after pathological stimuli such as stroke. mPT blockers, such as cyclosporin A and bongkrekic acid, have shown neuroprotective effects in animal models of ischemia. Several inhibitors of Cyt c release have shown promise in models of neuronal apoptosis. STRAVROSKAYA et al. (71) identified several drugs, including antidepressants and antipsychotics, capable of delaying the mPT. Interestingly, promethazine at clinically achievable doses inhibits mPT, and was protective both in vitro as well as in mouse models of stroke.
In the last portion of the apoptotic pathway, referred to as the execution phase, the participation of proteases and endonucleases has been described. A number of studies already indicated the prominent role of the cysteine proteases of the calpain and caspase families in apoptosis following brain ischemia. Proteolytic activities of these proteases degrade various cytoskeletal proteins and integral membrane proteins, destabilizing cellular structural integrity and leaving neurons within the ischemic penumbra to an inevitable death (60) . Some current studies have unequivocally confirmed the neuronal apoptosis in ischemia and showed that administration of calpain and caspase inhibitors alone or in combination can provide functional neuroprotection in various animal models of cerebral ischemia. However, further investigations are necessary for improvements in the structural design of calpain and caspase inhibitors for persistent therapeutic efficacy in animal models of stroke and for clinical trials in the future.
Other treatments
The potential for neuroprotection of hypothermia has long been suspected. In fact hypothermia is an essential method of cerebral protection during circulatory arrest. Most likely, hypothermia exerts multiple and synergistic effects on brain metabolism. Hypothermia reduces cerebral metabolic activity and the oxygen demand. Victims of near-drowning in icecold waters can have a remarkable neurological recovery even after prolonged cerebral ischemia (84) . Hypothermia decreases the cerebral metabolic rates of glucose and oxygen and slows ATP breakdown (21) . In the range of 22°C to 37°C, brain oxygen consumption is reduced by 5% for every degree fall in body temperature (33) . However, the most important mechanisms that cause the strong neuroprotection provided by induced hypothermia are still a matter of debate and are probably multiple. Some of the suggested mechanisms reported in the literature include the reduction of neurotransmitter release during ischemia (including glutamate) (52), reduced inflammation, and reduced free radical generation. Hypothermia lowers metabolic rate, limits edema formation, and interrupts necrosis/apoptosis (73, 81) . In addition, hypothermia reduces intracellular calcium rises after ischemia due to impaired glutamate-mediated calcium influx (73) .
Advantages of surface cooling are that it requires neither advanced equipment nor expertise in catheter placement and averts the risks associated with central venous catheter placement. Cooling through external methods, however, requires many hours to reach and maintain a temperature below 35 °C, and in most cases demands the use of sedatives and paralytics to prevent discomfort and shivering. In addition, cooling of the skin leads to vasoconstriction and reduces the heat exchange in cooled patients, which makes temperature control very difficult. This may lead to target temperature overshoot and lack of control during passive rewarming, which may be associated with reactive brain edema. In patients who are awake, surface cooling is only achieved as an approach for mild hypothermia and for fever control. New surface cooling devices, such as energy-transferring skin pads (48) , may demonstrate a reduction in the time to target temperature and allow better temperature control. In a pilot trial (17) , treatment with paracetamol at 6 grams daily, compared with placebo, led to a 0.3 ºC reduction in body temperature in normothermic patients. This temperature reduction is of potential but unproven clinical benefit. In another study (14, 46) 40 patients were randomly assigned either standard care or endovascular intravenous cooling to 33 ºC for 24 hours within 12 hours of symptom onset. Hypothermia was well tolerated, but clinical and MRI measures did not differ between treatment groups. Further studies are needed to determine whether hypothermia improves outcome. The use of hypothermia might also be limited by its substantial side-effects which include shivering and infections. The application of hypothermia is also limited by practical considerations such as the need for treatment in an intensive care unit.
Despite the absence of evidence, heparin and heparinoids are still frequently used. According to the American and European Guidelines, the use of anticoagulants should be restricted to special cases, such as cerebral venous sinus thrombosis and possibly arterial dissections (2, 13, 19, 20, 54, 62, 66) . Several studies have shown no benefit of anticoagulation in acute ischemic stroke (1, 3, 11, 12, 67) . Therefore, anticoagulants such as heparin have no role in the routine management of acute ischemic stroke.
Acute aspirin has been tested in two large trials. The International Stroke Trial (76) compared aspirin alone with two different doses of heparin within 48 hours of symptom onset. Aspirin was associated with significantly fewer recurrent ischemic strokes and no significant increase in hemorrhagic strokes at 14 days. The rate of death or dependency did not differ between the two groups at six months. The Chinese Acute Stroke Trial (9, 73) also compared aspirin with placebo within 48 hours of symptom onset. Significantly fewer recurrent ischemic strokes occurred in the aspirin group, but the number of hemorrhagic strokes increased. Aspirin given within 48 hours of acute ischemic stroke seems to reduce death and disability. However, the use of aspirin in conjunction with alteplase might increase the risk of bleeding (39, 75) . Acute aspirin is recommended for patients with acute ischemic stroke who are ineligible for thrombolytic therapy.
Minocycline, a semisynthetic second generation derivate of tetracycline, was show to have clear beneficial neuroprotective effects in animal models of stroke (85) . The proposed mechanism of minocycline include its anti-inflammatory effect, reduction of microglial activation, matrix metalloproteinase reduction, nitric oxide production, and inhibition of apoptotic cell death (for review see 35). Recently in an open-label, evaluator-blinded study, minocycline at a dosage of 200 mg was administrated orally for 5 days. The therapeutic window of time was 6 to 24 h after onset of stroke. Data from NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI) were evaluated. Patients with acute stroke had significantly better outcome with minocycline treatment compared with placebo (38) .
Besides the effect of statin treatment in stroke prevention, it has also been shown that statins (HMG-CoA reductase inhibitors) have other beneficial effects and these may be independent of the subject's basal lipid levels (47, 86) . In fact, recent studies suggest a neuroprotective power in the acute phase of stroke. It is well known that statins have direct influences on endothelial function by up-regulating endothelial nitric oxide synthase, inhibiting inducible nitric oxide synthase, reducing plaque stability due to an antithrombotic and anti-inflammatory mechanism, modulating the immune system, and enhancing vasomotor reactivity. These properties, also called pleiotropic effects, are responsible for the potentially beneficial use of statins in acute ischemic stroke. A recent study demonstrated the beneficial effects of statins (atorvastatin, 20 mg) in the acute phase of stroke by attenuating the pro-inflammatory cytokine responses as well as the expression of adhesion molecules that accompany cerebral ischemia. These protective effects are also related with less infarct volume and a more favorable outcome at three months from stroke onset (53) . In the National Institutes of Health Suburban Hospital Stroke Program Study, 22% of patients were taking a statin when they were admitted. In this observational study, 51% of patients taking these drugs had a good outcome compared with 38% of those not taking statins (83) . Another study (18) included patients with stroke of which 18% were using statins when admitted. Better prognosis at 3 months was significantly more frequent in the statin group, indicating that these drugs may provide benefits for the long-term functional outcome when administered before the onset of cerebral ischemia. Additionally, the preliminary results of a pilot clinical trial have been communicated, suggesting that simvastatin therapy initiated in the acute phase of ischemic stroke might improve neurological outcomes as well. Statins have also been found to be useful when given in combination with thrombolytic therapy. In an embolic model of cerebral ischemia in rats, the combination treatment with atorvastatin and t-PA exerts a neuroprotective effect when administered 4 hours after stroke (14) . In clinical practice, a recent study has evaluated 145 patients with a stroke involving the middle cerebral artery who received tissue plasminogen activator treatment (6) . Statistically significant differences were found among 27.3% of patients who were using statins at the time of the index stroke and were functionally independent at 3 months, as compared with 13.6% among the group of patients who were dependent or dead.
Systemic hypertension in the acute phase of ischemic stroke is common and is believed to be a physiologic response that attempts to maintain an adequate cerebral perfusion pressure within the ischemic penumbra (59) . While appropriate in primary and secondary stroke prevention, the lowering of elevated blood pressure (BP) in the acute setting of ischemic stroke has been a matter of debate for several years. Some studies have suggested that it could result in the extension and worsening of stroke symptoms, resulting in unfavorable outcomes (8, 22, 40, 45, 55, 56, 78) . In contrast, other experimental and clinical studies demonstrated that a cautious reduction of BP may even improve the prognosis in acute cerebral ischemia (24, 45) . The current recommendation to tolerate acute hypertension in cerebral ischemia is based on the concept of disturbed autoregulation of cerebral blood flow in the penumbra surrounding the zone of necrosis. However, the ACCESS study (a multicenter phase II study) (31, 64) showed that candesartan in the acute phase of ischemic stroke was safe, with no cerebrovascular events occurring as a result of hypotension. Encouraged by the success of ACCESS, several studies dealing with antihypertensive drugs for acute ischemic stroke are ongoing, including COSSACS (to determine whether antihypertensive therapy should be continued in the acute stroke setting), CHHIPS (to determine the extent to which BP should be lowered in the acute stroke setting), and SCAST (to assess whether candesartan given to patients with elevated BP in the acute phase of stroke reduces the cardiovascular risk).
Elevated blood glucose is common in the early phase of stroke. Hyperglycemia, defined as blood glucose level >108mg/dL, may influence neuronal damage through accentuated tissue acidosis and lactate generation. Moderately and severely increased blood glucose has been found to further deteriorate the metabolic state and mitochondrial function in the area of the ischemic penumbra. Moreover, the blood-brain barrier is vulnerable to hyperglycemia presumably through the liberation of lactic acid and free radicals (42) . However, although diabetes and hyperglycemia are associated with worse outcomes in acute ischemic stroke, the threshold blood sugar levels to initiate treatment with insulin are arbitrary and the efficacy and safety of aggressive glycemic control is unknown. Furthermore, the level of target glucose concentrations is not the same for the different current target values in the published guidelines: EUSI: <10nmol/L; ASA: <16.6 nmol/L. A reasonable target in most cases of lower blood glucose levels is between 100 and 200 mg/dl, although levels of glycemia >150 mg/dL should probably be avoided and insulin therapy should be initiated (16) . Most recently, The United Kingdom Glucose Insulin in Stroke Trial (GIST-UK), a multicenter randomized trial, demonstrates the safety of administering a glucose-potassium-insulin infusion in acute phase stroke patients with the aim of keeping glucose level between 72-126 mg/dL. However, until further results prove the effectiveness of this approach, it cannot be regarded as standard practice.
Conclusion
After the NINDS rt-PA study publication in 1995, the classical approach to ischemic stroke started to change. However, more than ten years later, less than 4% of patients receive treatment with alteplase. Moreover, IV thrombolysis has many limitations and there are no broadly accepted alternatives for nonresponders. So, neurologists are currently involved in new investigations to fight against these limitations. In the coming years, medicine will have to find effective neuroprotection with the ability to prolong the window of opportunity for time-sensitive ischemic tissue. It will probably become necessary to improve our current methodology for investigations and assume the STAIR recommendations. Finding effective neuroprotection will require identifying strategies to protect not only neurons, but also vascular and glial cells. Furthermore, in spite of the development of new drugs capable of prolonging the efficacy and improving the safety of clot lysis, reperfusion therapy in ischemic stroke incorporates pharmaceutical and mechanical therapies. Endovascular devices and acute angioplasty will likely have a prominent role, as has occurred in acute coronary syndrome management. However, the paramount advance in acute stroke therapy may be the use of multi-modal imaging techniques and serum biomarkers to predict with reasonable accuracy the location and amount of irreversible ischemic damage. This fact will change the idea of a general timetable in thrombolysis to an individualized timetable in ischemic stroke. El ictus representa la segunda causa de muerte y la primera de incapacidad en los paí-ses desarrollados. Pese a su frecuencia y gravedad, hasta hace pocos años no se disponía de tratamientos eficaces en la fase aguda, lo que condicionaba una actitud nihilista en todo el proceso terapéutico. En la última década se ha conseguido demostrar la efectividad de la administración precoz de tratamiento intravenoso trombolítico con rtPA en el ictus isqué-mico, por lo que tanto la FDA americana como la agencia europea del medicamento han autorizado su uso, si bien con restricciones diferentes. Además, la monitorización de los paráme-tros biológicos y estandarización de los cuidados médicos y de enfermería en los primeros días, realizados en las Unidades de Ictus, han demostrado también su eficacia terapéutica. En la actualidad el esfuerzo investigador en el ictus intenta encontrar moléculas que solas o en combinación trasladen a la práctica clínica la capacidad de neuroprotección que muchas de ellas ya han demostrado en el laboratorio o en los modelos animales. Sin embargo, hasta la fecha este esfuerzo no ha sido recompensado plenamente y científicos básicos y clínicos tendrán que intensificar su trabajo y comunicación para lograr al fin estrategias que permitan mantener viable el tejido cerebral sometido a agresión tras el ictus.
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